Characteristics of patients in the DSA (receiving desensitization) and control groups
| . | DSA group (n = 37), (%,range or SD) . | Control group (n = 345), (%, range or SD) . | P value . |
|---|---|---|---|
| Age (y), median (range) | 51 (19-66) | 47 (18-72) | .374 |
| Sex: female | 31 (83.8) | 128 (37.1) | <.001 |
| Sex mismatch | 17 (46.0) | 154 (44.6) | .507 |
| Diagnosis | .887 | ||
| AML/MDS | 21 (56.8) | 200 (58.0) | |
| Others | 16 (43.2) | 145 (42.03) | |
| ABO mismatch | .368 | ||
| Minor | 5 (14.7) | 57 (15.6) | |
| Major | 3 (8.8) | 55 (16.0) | |
| Bidirectional | 1 (2.9) | 3 (0.9) | |
| Donor-recipient relation | .002 | ||
| Child | 25 (67.6) | 44 (44.1) | |
| Sibling | 7 (18.9) | 150 (43.5) | |
| Parent | 3 (8.1) | 40 (11.6) | |
| Other | 2 (5.4) | 3 (0.9) | |
| Child donor to mother recipient | 24 (64.9) | 64 (18.6) | <.001 |
| DRI-R (n = 309) | .170 | ||
| Low | 3 (9.7) | 32 (12.1) | |
| Intermediate | 14 (45.2) | 114 (43.2) | |
| High | 7 (22.6) | 92 (34.9) | |
| Very high | 7 (22.6) | 26 (9.9) | |
| Prior autologous transplant | 2 (6.1) | 29 (8.4) | 1.000 |
| CR 1/2 | 11 (34.4) | 128 (37.1) | .460 |
| Median HCT-CI (range) | 2 (0-7) | 2 (0-9) | .226 |
| Conditioning regimen intensity | .056 | ||
| MAC | 27 (73.0) | 195 (56.5) | |
| NMA/RIC | 10 (27.0) | 150 (43.5) | |
| Conditioning regimen | |||
| Flu-Mel (±TBI, thiotepa) | 26 (70.3) | 292 (84.6) | .003 |
| Flu-Bu (±TBI, thiotepa) | 5 (13.5) | 43 (12.5) | |
| Others (Flu-TBI, Flu-Cy) | 6 (16.2) | 10 (2.9) | |
| Stem source: marrow | 21 (56.8) | 282 (81.7) | .001 |
| Buffy coat infusion | 27 (77.1) | NA | |
| Antibody specificity | |||
| HLA class I | 14 (37.8) | NA | |
| HLA class II | 12 (32.4) | NA | |
| HLA class I and II | 11 (29.7) | NA | |
| Predesensitization MFI level, mean (SD) | 10 198.2 (8618.6) | NA | |
| Postdesensitization MFI level, mean (SD) | 5937.2 (8336) | NA | |
| Initial C1q positivity (n = 30) | 14 (46.7) | ||
| Pretransplant C1q positivity (n = 29) | 8 (27.6) | NA |
| . | DSA group (n = 37), (%,range or SD) . | Control group (n = 345), (%, range or SD) . | P value . |
|---|---|---|---|
| Age (y), median (range) | 51 (19-66) | 47 (18-72) | .374 |
| Sex: female | 31 (83.8) | 128 (37.1) | <.001 |
| Sex mismatch | 17 (46.0) | 154 (44.6) | .507 |
| Diagnosis | .887 | ||
| AML/MDS | 21 (56.8) | 200 (58.0) | |
| Others | 16 (43.2) | 145 (42.03) | |
| ABO mismatch | .368 | ||
| Minor | 5 (14.7) | 57 (15.6) | |
| Major | 3 (8.8) | 55 (16.0) | |
| Bidirectional | 1 (2.9) | 3 (0.9) | |
| Donor-recipient relation | .002 | ||
| Child | 25 (67.6) | 44 (44.1) | |
| Sibling | 7 (18.9) | 150 (43.5) | |
| Parent | 3 (8.1) | 40 (11.6) | |
| Other | 2 (5.4) | 3 (0.9) | |
| Child donor to mother recipient | 24 (64.9) | 64 (18.6) | <.001 |
| DRI-R (n = 309) | .170 | ||
| Low | 3 (9.7) | 32 (12.1) | |
| Intermediate | 14 (45.2) | 114 (43.2) | |
| High | 7 (22.6) | 92 (34.9) | |
| Very high | 7 (22.6) | 26 (9.9) | |
| Prior autologous transplant | 2 (6.1) | 29 (8.4) | 1.000 |
| CR 1/2 | 11 (34.4) | 128 (37.1) | .460 |
| Median HCT-CI (range) | 2 (0-7) | 2 (0-9) | .226 |
| Conditioning regimen intensity | .056 | ||
| MAC | 27 (73.0) | 195 (56.5) | |
| NMA/RIC | 10 (27.0) | 150 (43.5) | |
| Conditioning regimen | |||
| Flu-Mel (±TBI, thiotepa) | 26 (70.3) | 292 (84.6) | .003 |
| Flu-Bu (±TBI, thiotepa) | 5 (13.5) | 43 (12.5) | |
| Others (Flu-TBI, Flu-Cy) | 6 (16.2) | 10 (2.9) | |
| Stem source: marrow | 21 (56.8) | 282 (81.7) | .001 |
| Buffy coat infusion | 27 (77.1) | NA | |
| Antibody specificity | |||
| HLA class I | 14 (37.8) | NA | |
| HLA class II | 12 (32.4) | NA | |
| HLA class I and II | 11 (29.7) | NA | |
| Predesensitization MFI level, mean (SD) | 10 198.2 (8618.6) | NA | |
| Postdesensitization MFI level, mean (SD) | 5937.2 (8336) | NA | |
| Initial C1q positivity (n = 30) | 14 (46.7) | ||
| Pretransplant C1q positivity (n = 29) | 8 (27.6) | NA |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; Bu, busulfan; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CR1/2, first or second complete remission; Cy, cyclophosphamide; Flu, fludarabine; MA, myeloablative conditioning; MDS, myelodysplastic syndrome; Mel, melphalan; MPN, myeloproliferative neoplasm; NA, not available; NMA, non-myeloablative intensity conditioning; RIC, reduced intensity conditioning; TBI, total body irradiation.